MarketScreener Homepage > Equities > Euronext Amsterdam > Galapagos NV GLPG BE0003818359

Report

Real-time Estimate Tradegate - 11/30 08:35:56 am
104.8	EUR		-0.29%

11/23

GALAPAGOS : Selvita to acquire Fidelta from Galapagos

11/23

GALAPAGOS : Selvita to acquire Fidelta from Galapagos

11/09

GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial

News

Press Releases

Official Publications

Sector news

MarketScreener Strategies

Analyst Recommendations

Communiqués de presse de la société GALAPAGOS NV

11/23	GALAPAGOS : Selvita to acquire Fidelta from Galapagos	AQ
11/23	GALAPAGOS : Selvita to acquire Fidelta from Galapagos	AQ
11/09	GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..	AQ
11/09	GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..	AQ
11/09	First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial	GL
11/09	OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent ..	AQ
11/05	GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..	AQ
11/05	GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..	AQ
11/05	OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhi..	GL
11/05	GALAPAGOS : reports Q3 2020 results	AQ
11/05	GALAPAGOS : reports Q3 2020 results	AQ
11/05	Galapagos reports Q3 2020 results	GL
11/03	GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..	AQ
11/02	GALAPAGOS : European Medicines Agency Validates Marketing Application for Filgot..	BU
11/02	GALAPAGOS : European medicines agency validates marketing application for ..	AQ
11/02	GALAPAGOS : European medicines agency validates marketing application for ..	AQ
11/02	European medicines agency validates marketing application for filgotin..	GL
10/27	GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program	AQ
10/27	GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program	AQ
10/27	Galapagos' R&D Roundtable showcases Toledo program	GL
10/16	GALAPAGOS : And servier report topline results for roccella phase 2 clinical tri..	AQ
10/16	Oxurion NV Business Update, Q3 2020	AQ
10/15	GALAPAGOS : and Servier report topline results for ROCCELLA Phase 2 clinical tri..	AQ
10/15	GALAPAGOS : and Servier report topline results for ROCCELLA Phase 2 clinical tri..	AQ
10/15	Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical tr..	GL
10/14	Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer	AQ
10/13	GILEAD SCIENCES INC. : - Phase 2b/3 Trial Shows Efficacy of Filgotinib for the I..	AQ
10/12	GALAPAGOS : Phase 2b/3 trial shows efficacy of filgotinib for the induction and ..	AQ
10/12	GALAPAGOS : Phase 2b/3 trial shows efficacy of filgotinib for the induction and ..	AQ
10/12	GALAPAGOS : Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and ..	BU
10/12	Phase 2b/3 trial shows efficacy of filgotinib for the induction and maintenan..	GL
10/09	Invitation OXURION R&D Investor Day, Virtual 15 October 2020 at 5.30pm CET/ 1..	AQ
09/30	Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtu..	AQ
09/30	GALAPAGOS : announces first dosing with Toledo compound GLPG3970 in psoriasis tr..	AQ
09/29	GALAPAGOS : announces first dosing with Toledo compound GLPG3970 in psoriasis tr..	AQ
09/29	GALAPAGOS : announces first dosing with Toledo compound GLPG3970 in psoriasis tr..	AQ
09/29	Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis ..	GL
09/28	Gilead Sciences, Inc. - Jyseleca Approved in Japan for Rheumatoid Arthritis	AQ
09/28	GILEAD SCIENCES : European Commission Grants Marketing Authorization for Jyselec..	AQ
09/25	GALAPAGOS : European commission grants marketing authorization for jyseleca®..	AQ
09/25	GALAPAGOS : European commission grants marketing authorization for jyseleca®..	AQ
09/25	GALAPAGOS : European Commission Grants Marketing Authorization for Jyseleca® ..	BU
09/25	European commission grants marketing authorization for jyseleca® (filgoti..	GL
09/25	CORRECTION : Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis	GL
09/25	CORRECTION : Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis	AQ
09/25	GALAPAGOS : Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis	AQ
09/25	Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis	GL
09/18	GALAPAGOS : increases share capital through subscription right exercises	AQ
09/18	GALAPAGOS : increases share capital through subscription right exercises	AQ
09/18	Galapagos increases share capital through subscription right exercises	GL
09/18	OXURION : Business Update, H1 2020	AQ
09/15	Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment C..	AQ
09/10	GALAPAGOS : Primary endpoint achieved with ziritaxestat in NOVESA trial in syst..	AQ
09/10	GALAPAGOS : Primary endpoint achieved with ziritaxestat in NOVESA trial in syst..	AQ
09/10	Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic scl..	GL
09/02	Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 fo..	AQ
08/26	Galapagos to present new insights in IPF and related clinical developments at..	GL
08/18	Galapagos announces that Gilead received a complete response letter for filgo..	GL
08/12	Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disea..	GL
08/06	GALAPAGOS : H1 Report 2020	PU
08/06	Galapagos reports solid H1 2020 progress	GL
07/27	GILEAD SCIENCES : and Galapagos Announce Positive European CHMP Opinion for Jyse..	AQ
07/24	Gilead and galapagos announce positive european chmp opinion for jys..	GL
07/24	GALAPAGOS : Gilead and Galapagos Announce Positive European CHMP Opinion for Jys..	BU
06/08	GILEAD SCIENCES : New Analyses of Phase 2 EQUATOR Clinical Program Support Durab..	AQ
06/05	GALAPAGOS : New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Eff..	BU
06/05	New analyses of phase 2 equator clinical program support durable ef..	GL
06/04	GALAPAGOS : Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profi..	BU
06/04	Filgotinib demonstrates durable efficacy and consistent safety profile..	GL
05/28	Galapagos increases share capital through subscription right exercises	GL
05/20	GALAPAGOS : Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3..	BU
05/20	Gilead and galapagos announce positive topline results of phase 2b/3..	GL
05/11	GALAPAGOS : Written questions	PU
05/07	GALAPAGOS : Q1 Report 2020 pdf	PU
05/07	On track for clinical read-outs and commercial readiness in 2020	GL

1 2 3 4 5 6 Next

Analysis

Gilead shares slide after FDA knocks back rheumatoid arthritis drug